ArticleJournal of public health (Oxford, England)2021
Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.
Article in Journal of public health (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan.Journal of global health · 2025Article
- Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan.BMC infectious diseases · 2023Article
- Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines.Acta tropica · 2022Article
- Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.Archives of virology · 2022Article
- Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms.BMC infectious diseases · 2022Article
- SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- SerumCovid database: Description and preliminary analysis of serological COVID-19 diagnosis in healthcare workers.PloS one · 2022Article
- IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi.PloS one · 2022Article
- Article
- COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.PLoS medicine · 2021Article
- Serologic response to SARS-CoV-2 in an African population.Scientific African · 2021Article
- Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.Epidemiology and infection · 2021Article
- Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Low uptake of COVID-19 prevention behaviours and high socioeconomic impact of lockdown measures in South Asia: Evidence from a large-scale multi-country surveillance programme.SSM - population health · 2021Article
- Tracking SARS-CoV-2 infection in India with serology.The Lancet. Global health · 2021Article
- Point of Care Testing for SARS-COV-2 Antibodies before doing Endoscopy.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent pandemic by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global emergency. There is large number of asymptomatic cases of SARS-CoV-2 that are not reported. Hence, serological evidence of SARS-CoV2 antibodies is warranted for a better estimation of the actual number of infected patients to limit the disease spread and to get an idea of herd immunity.
methodsThis is a cross-sectional study conducted from May 2020 to July 2020 at National Institute of Blood Diseases at Pakistan. The study includes healthcare workers (HCWs), community and industrial workers. The anti-SARS-CoV-2 test was performed by electrochemiluminescence immunoassay analyzer.
resultsA total of 1675 samples have been received from three groups of population. The percentage positivity for industrial employees is high (50.3%) for HCW (13.2%) and community population (34%).Total percentage for positive antibodies result is ~36%.
conclusionOur seroprevalence is 36%, which still far from herd immunity that needs to be at least 60-70% in population. If we consider acquiring 60% seroprevalence in next few months, then herd immunity is not far from reality, provided the antibodies did not decline with time. Although the current study is based on a small sample of participants, the findings suggest a study with larger population to implement stronger and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.